Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in moderate to severe atopic dermatitis
NCT03822832Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2019
- Primary completion
- Jan 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Spesolimab with Placebo (2 arms). Primary endpoint: Percentage Change From Baseline in Eczema Area and Severity Index at 16 weeks. Started Feb 2019; status: completed.
02
Drugs
spesolimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03822832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03822832.